HCWB Q1 2026 Earnings Significant EPS Surprise with No Product Revenue REVB Q1 2026 Earnings Staggering EPS Miss Highlights Ongoing Clinical Development Costs PROP Q1 2026 Earnings Significant EPS Miss but Stock Climbs 9 AMWD Q1 2026 Earnings Strong EPS Beat Driven by Operational Efficiency PRS Q1 2026 Earnings Robust EPS Beat of 154 Highlights Operational Strength Amid Stable FixedIncome Performance CC Q1 2026 Earnings Chemours Surpasses Estimates with Strong EPS Surprise